BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23473356)

  • 1. Augmentation of venlafaxine with bupropion: risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression.
    Andrade C
    J Clin Psychiatry; 2013 Feb; 74(2):e119-21. PubMed ID: 23473356
    [No Abstract]   [Full Text] [Related]  

  • 2. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of bupropion with SRIs and venlafaxine.
    Spier SA
    Depress Anxiety; 1998; 7(2):73-5. PubMed ID: 9614595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bupropion-induced neck and shoulder pain.
    Sansone RA; Sansone LA
    Pharmacopsychiatry; 2009 Sep; 42(5):203-4. PubMed ID: 19724984
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series.
    Paslakis G; Gilles M; Deuschle M
    J Clin Psychopharmacol; 2010 Aug; 30(4):473-4. PubMed ID: 20631572
    [No Abstract]   [Full Text] [Related]  

  • 7. Bupropion: efficacy and safety in the treatment of depression.
    Saiz Ruiz J; Gibert J; Gutiérrez Fraile M; Bobes J; Vallejo J; Iglesias C; Iriarte V
    Actas Esp Psiquiatr; 2011; 39 Suppl 1():1-25. PubMed ID: 22983817
    [No Abstract]   [Full Text] [Related]  

  • 8. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
    Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
    J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine plus venlafaxine in treatment-resistant depression.
    Devarajan S; Dursun SM
    J Psychopharmacol; 2005 Jul; 19(4):434-5. PubMed ID: 15983004
    [No Abstract]   [Full Text] [Related]  

  • 10. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
    Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
    Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine-associated serotonin syndrome and manic episode in a geriatric depressive patient.
    Liau CH; Shen WW; Su KP
    Psychiatry Clin Neurosci; 2006 Feb; 60(1):121-2. PubMed ID: 16472373
    [No Abstract]   [Full Text] [Related]  

  • 12. Venlafaxine plus mirtazapine as first-line treatment for melancholia: preliminary results.
    Ruiz-Doblado S; Rueda-Villar T; Zurita-Gotor P; Sanz-Cortes S
    J Psychopharmacol; 2010 Dec; 24(12):1837. PubMed ID: 21138931
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
    Hwang JP; Yang CH; Tsai SJ
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):189-90. PubMed ID: 14758586
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose-dependent Venlafaxine-induced sinus tachycardia.
    Abozguia K; Chudley S; Gammage M
    Int J Cardiol; 2006 Oct; 113(1):E9-10. PubMed ID: 16989912
    [No Abstract]   [Full Text] [Related]  

  • 15. [Selective noradrenaline-dopamine reuptake inhibition (SNDRI). More latitude for antidepressive therapy].
    MMW Fortschr Med; 2007 May; 149 Suppl 2():88-9. PubMed ID: 17724976
    [No Abstract]   [Full Text] [Related]  

  • 16. Perceptual disturbances associated with low-dose bupropion sustained-release treatment.
    Liu CY; Chien YS
    J Clin Psychopharmacol; 2007 Oct; 27(5):543-4. PubMed ID: 17873707
    [No Abstract]   [Full Text] [Related]  

  • 17. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.
    Hannan N; Hamzah Z; Akinpeloye HO; Meagher D
    J Psychopharmacol; 2007 Mar; 21(2):161-4. PubMed ID: 17329295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium and venlafaxine interaction: a case of serotonin syndrome.
    Adan-Manes J; Novalbos J; López-Rodríguez R; Ayuso-Mateos JL; Abad-Santos F
    J Clin Pharm Ther; 2006 Aug; 31(4):397-400. PubMed ID: 16882112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not neglecting therapy of depression in the elderly].
    MMW Fortschr Med; 2006 Apr; 148(16):56-7. PubMed ID: 16688953
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients.
    Song HR; Jung YE; Wang HR; Woo YS; Jun TY; Bahk WM
    Psychiatry Clin Neurosci; 2012 Aug; 66(5):457-9. PubMed ID: 22834666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.